Company research / VCYT

Veracyte, Inc. (VCYT)

SEC name VERACYTE, INC. · CIK 0001384101 · Nasdaq · Services-Medical Laboratories

  • Sector Services
  • Incorporated DE
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, Veracyte, Inc. reported revenue of $517.14M. Revenue grew 16.0% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $561.90M.

Key ratios (year ended 2025-12-31)

70.1%
Gross margin
11.2%
Operating margin
12.8%
Net margin
5.1%
Return on year-end equity
16.0%
Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 4 (ownership change) · 2026-09-22

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-06-30
2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$561.90M$517.14M$445.76M$361.05M$296.54M$219.51M$117.48M$120.37M$92.01M$71.95M$65.08M
Cost of Revenuen/an/an/an/an/an/an/a$36.08M$33.08M$28.20M$25.46M
Gross Profit$402.96M$362.53M$298.14M$229.68M$175.68Mn/an/an/an/an/an/a
R&D Expense$93.37M$70.81M$69.29M$57.30M$40.60M$29.84M$17.20M$14.85M$14.82M$13.88M$15.32M
Operating Income$105.77M$57.78M$16.14M-$85.80M-$41.08M-$81.90M-$35.39M-$15.13M-$22.23M-$26.54M-$28.80M
Depreciation & Amortization$20.83M$21.41M$23.46M$27.19M$25.93M$19.59M$7.94M$4.12M$3.92M$3.84M$3.51M
EBITDA$126.60M$79.19M$39.60M-$58.61M-$15.15M-$62.31M-$27.45M-$11.01M-$18.31M-$22.70M-$25.29M
Net Income$114.48M$66.35M$24.14M-$74.40M-$36.56M-$75.56M-$34.91M-$12.60M-$23.00Mn/an/a
EPS (Diluted)n/a$0.82$0.31-$1.02-$0.51-$1.11-$0.66-$0.27n/an/an/a
Total Assets$1.49B$1.41B$1.30B$1.11B$1.16B$1.19B$457.16M$275.21M$120.64M$78.67M$101.03M
Total Liabilities$97.96M$96.44M$124.07M$70.80M$81.22M$91.31M$35.93M$35.76M$40.88M$41.44M$41.45M
Shareholders' Equity$1.39B$1.31B$1.18B$1.04B$1.08B$1.10B$421.23M$239.46M$79.75M$37.23M$59.58M
Cash & Equivalents$299.52M$362.58M$239.09M$216.45M$154.25M$173.20M$349.36M$159.32M$78.00M$33.89M$59.22M
Operating Cash Flow$178.38M$136.31M$75.10M$44.22M$7.54M-$31.62M-$9.71M-$3.23M-$13.52M-$23.91M-$27.98M
Capital Expenditures$12.39M$9.68M$11.29M$9.96M$8.55M$5.38M$2.84M$2.76M$1.87M$1.75M$4.21M
Free Cash Flow$165.99M$126.63M$63.81M$34.26M-$1.01M-$37.00M-$12.55M-$5.99M-$15.39M-$25.67M-$32.19M
Shares Outstanding80.36M79.36M77.77M73.26M71.96M71.12M58.20M49.63M40.86M33.76M33.76M
Weighted Average Diluted Sharesn/a80.57M78.16M72.64M71.55M67.89M53.24M46.14Mn/an/an/a
EPS (Basic)n/a$0.84$0.32-$1.02-$0.51-$1.11-$0.66-$0.27n/an/an/a

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView